Marvin A. H. Berrevoets

Marvin A. H. Berrevoets

Auto-generated profile, based on publicly available information

Marvin A. H. Berrevoets

Radboud Center for Infectious Diseases, Radboud university medical center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
TTThomas Timmers
Thomas Timmers
LJLoes Janssen
Loes Janssen
JSJoep Stohr
Joep Stohr
JMJean Luc Murk
Jean Luc Murk
MBM A H Berrevoets
M A H Berrevoets
Background: The coronavirus disease (COVID-19) situation demands a lot from citizens, health care providers, and governmental institutions. Citizens need to cope with guidelines on social interaction, work, home isolation, and symptom recognition. Additionally, health care providers and policy makers have to cope with unprecedented and unpredictable pressure on the health care system they need to manage. By providing citizens with an app, they always have access to the latest information and can assess their own health. This data could be used to support policy makers and health care providers to get valuable insights in the regional distribution of infection load and health care consumption. Objective: The aim of this observational study is to assess people’s use of an app to support them with COVID-19 education, self-assessment, and monitoring of their own health for a 7-day period. In addition, we aim to assess the usability of this data for health care providers and policy makers by applying it to an interactive map and combining it with hospital data. The secondary outcomes of the study were user’s satisfaction with the information provided in the app, perceived usefulness of the app, health care providers they contacted, and the follow-up actions from this contact. Methods: This observational cohort study was carried out at the nonacademic teaching hospital “Elisabeth Twee Steden” (ETZ) in Tilburg, Netherlands. From April 1, 2020, onwards ETZ offered the COVID-19 education, self-assessment, and symptom tracking diary to their already existing app for patient education and monitoring. Results: Between April 1 and April 20, 2020, a total of 6194 people downloaded the app. The self-assessment functionality was used abundantly to check one’s health status. In total, 5104 people responded to the question about severe symptoms, from which 242 indicated to suffer from severe symptoms. A total of 4929 people responded to the question about mild symptoms, from which 3248 indicated to suffer from these. The data was successfully applied to an interactive map, displaying user demographics and health status. Furthermore, the data was linked to clinical data. App users were satisfied with the information in the app and appreciated the symptom diary functionality. In total, 102 users reached out to a health care provider, leading to 91 contacts. Conclusions: Our study demonstrated the successful implementation and use of an app with COVID-19 education, self-assessment, and a 7-day symptom diary. Data collected with the app were successfully applied to an interactive map. In addition, we were able to link the data to COVID-19 screening results from the hospital’s microbiology laboratory. This data could be used to support policy makers and health care providers to get valuable insights in the regional distribution of infection load and health care consumption. Trial Registration: Netherlands Trial Register NL8501; https://www.trialregister.nl/trial/8501

23 March 2017 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
MBMarvin A.H. Berrevoets
Marvin A.H. Berrevoets
IKIlse J.E. Kouijzer
Ilse J.E. Kouijzer
EAErik H.J.G. Aarntzen
Erik H.J.G. Aarntzen
MJMarcel J.R. Janssen
Marcel J.R. Janssen
Lioe-Fee de Geus-OeiLioe-Fee de Geus-Oei
Lioe-Fee de Geus-Oei
CBChantal P. Bleeker-Rovers
Chantal P. Bleeker-Rovers
Metastatic infection is an important complication of Staphylococcus aureus bacteremia (SAB). Early diagnosis of metastatic infection is crucial, as specific treatment is required. However, metastatic infection can be asymptomatic and difficult to detect. In this study, we investigated the role of 18F-FDG-PET/CT in patients with SAB for detection of metastatic infection and its consequences for treatment and outcome. Methods: All patients with SAB at Radboud university medical center were included between January 2013 and April 2016. Clinical data and results of 18F-FDG-PET/CT and other imaging techniques, including echocardiography, were collected. Primary outcomes were newly diagnosed metastatic infection by 18F-FDG-PET/CT, subsequent treatment modifications, and outcome. Results: A total of 184 patients were included and 18F-FDG-PET/CT was performed in 105 patients of whom 99 had a high-risk bacteremia. 18F-FDG-PET/CT detected metastatic infectious foci in 73.7% of these high-risk patients. In 71.2% of patients with metastatic infection, no signs and symptoms suggesting metastatic complications were present before 18F-FDG-PET/CT was performed. 18F-FDG-PET/CT led to a total of 104 treatment modifications in 74 patients. Three-month mortality was higher in high-risk bacteremia patients without 18F-FDG-PET/CT performed compared to those in whom 18F-FDG-PET/CT was performed (32.7% versus 12.4%, P = 0.003). In multivariate analysis, 18F-FDG-PET/CT was the only factor independently associated with reduced mortality (P = 0.005; OR, 0.204; 95% CI, 0.066-0.624). A higher co-morbidity score was independently associated with increased mortality (P = 0.003; OR, 1.254; 95% CI, 1.078-1.457). Conclusion: 18F-FDG-PET/CT is a valuable technique for early detection of metastatic infectious foci, often leading to treatment modification. Performing18F-FDG-PET/CT is associated with significantly reduced three-month mortality.

12 November 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
MBMarvin A H Berrevoets
Marvin A H Berrevoets
AOAnke J M Oerlemans
Anke J M Oerlemans
MTMirjam Tromp
Mirjam Tromp
BKBart Jan Kullberg
Bart Jan Kullberg
JOJaap Ten Oever
Jaap Ten Oever
MHMarlies E Hulscher
Marlies E Hulscher
Objectives Current outpatient parenteral antimicrobial therapy (OPAT) guidelines recommend delivering patient-centred care. However, little is known about what patients define as good quality of OPAT care and what their needs and preferences are. The aim of this qualitative study is to explore the patients’ perspective on high-quality care, and to explore what patient-centred care means to adult OPAT patients. Design and setting This is an explorative, descriptive study using qualitative methods. We conducted focus group interviews with 16 adult patients (5 female, 11 male) from 3 different hospitals, who received OPAT and 2 individual semistructured interviews with their informal caregivers in the Netherlands. We used purposive sampling to ensure diversity of participants. We used the eight Picker principles of patient-centredness to guide data collection and analysis. Results Participants reported several elements considered as important for patient-centred OPAT care, like patient involvement in the decision-making process, a responsible OPAT lead, intensive collaboration between all disciplines involved, information provision and adherence to hygiene guidelines. Two central dimensions emerged as essential constituents of patient-centred OPAT care: freedom and safety. Both are heavily influenced by the behaviours of healthcare professionals and by organisational aspects beyond the direct influence of these professionals. Conclusion This study provides insights into the needs and preferences of adult patients who receive OPAT care. Future interventions directed at the improvement of patient-centredness of OPAT care should focus on elements that enhance patients’ feelings of freedom and safety.

14 December 2018 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
MBMarvin A.H. Berrevoets
Marvin A.H. Berrevoets
IKIlse J.E. Kouijzer
Ilse J.E. Kouijzer
KSKitty Slieker
Kitty Slieker
EAErik H.J.G. Aarntzen
Erik H.J.G. Aarntzen
BKBart Jan Kullberg
Bart Jan Kullberg
CBChantal P. Bleeker-Rovers
Chantal P. Bleeker-Rovers
Current guidelines recommend intravenous antibiotic therapy for at least 4 wk in patients with high-risk Staphylococcus aureus bacteremia (SAB), because of the risk for metastatic infection. We evaluated the safety of a shorter duration of treatment in patients with high-risk SAB without signs of metastatic infection at presentation, using standard 18F-FDG PET/CT and echocardiography. Methods: Retrospective analyses were performed of patients with SAB admitted between 2013 and 2017 in 2 medical centers. Patients with risk factors for complicated bacteremia (community acquisition, persistently positive blood cultures, >72 h of fever, or foreign body materials present), a normal echocardiography result, and 18F-FDG PET/CT without signs of metastatic infection were included (cases) and compared with patients with uncomplicated bacteremia (absence of any of the risk factors and no known metastatic disease, controls). Primary outcomes were 3-mo SAB-specific mortality rate and recurrent infection. The secondary outcome was overall mortality. Results: We included 36 cases and 40 controls. Both groups had a similar treatment duration (15.9 vs. 15.4 d). No deaths occurred as a consequence of SAB in the cases, compared with 1 in the control group. One relapse occurred in the case group and 2 in the control group. Overall mortality did not differ between the groups (19.4% vs. 15.0%, P = 0.64). Conclusion: This study suggests that intravenous treatment for 2 wk in high-risk patients with SAB without endocarditis and absence of metastatic infection on 18F-FDG PET/CT is safe. A diagnostic-driven approach using 18F-FDG PET/CT to determine treatment duration in high-risk SAB seems feasible and allows tailoring treatment to individual patients.

20 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
WVWilhelm A.J.W. Vos
Wilhelm A.J.W. Vos
AGAlbert Groenendijk
Albert Groenendijk
MBMarc J. T. Blaauw
Marc J. T. Blaauw
LELouise E. van Eekeren
Louise E. van Eekeren
ANAdriana Navas
Adriana Navas
AVAndre J. A. M. van der Ven
Andre J. A. M. van der Ven
Background: Even during long-term combination antiretroviral therapy (cART), people living with HIV (PLHIV) have a dysregulated immune system, characterized by persistent immune activation, accelerated immune ageing and increased risk of non-AIDS comorbidities. A multi-omics approach is applied to a large cohort of PLHIV to understand pathways underlying these dysregulations in order to identify new biomarkers and novel genetically validated therapeutic drugs targets.Methods: The 2000HIV study is a prospective longitudinal cohort study of PLHIV on cART. In addition, untreated HIV spontaneous controllers were recruited. In-depth multi-omics characterization will be performed, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and metagenomics, functional immunological assays and extensive immunophenotyping. Furthermore, the latent viral reservoir will be assessed through cell associated HIV-1 RNA and DNA, and full-length individual proviral sequencing on a subset. Clinical measurements include an ECG, carotid intima-media thickness and plaque measurement, hepatic steatosis and fibrosis measurement as well as psychological symptoms and recreational drug questionnaires. Additionally, considering the developing pandemic, COVID-19 history and vaccination was recorded. Participants return for a two-year follow-up visit. The 2000HIV study consists of a discovery and validation cohort collected at separate sites to immediately validate any finding in an independent cohort.Results: Overall, 1895 PLHIV from four sites were included for analysis, 1559 in the discovery and 336 in the validation cohort. The study population was representative of a Western European HIV population, including 288 (15.2%) cis-women, 463 (24.4%) non-whites, and 1360 (71.8%) MSM (Men who have Sex with Men). Extreme phenotypes included 114 spontaneous controllers, 81 rapid progressors and 162 immunological non-responders. According to the Framingham score 321 (16.9%) had a cardiovascular risk of >20% in the next 10 years. COVID-19 infection was documented in 234 (12.3%) participants and 474 (25.0%) individuals had received a COVID-19 vaccine.Conclusion: The 2000HIV study established a cohort of 1895 PLHIV that employs multi-omics to discover new biological pathways and biomarkers to unravel non-AIDS comorbidities, extreme phenotypes and the latent viral reservoir that impact the health of PLHIV. The ultimate goal is to contribute to a more personalized approach to the best standard of care and a potential cure for PLHIV.

6 May 2019 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MBMarvin A H Berrevoets
Marvin A H Berrevoets
JOJaap Ten Oever
Jaap Ten Oever
AOAnke J M Oerlemans
Anke J M Oerlemans
BKBart Jan Kullberg
Bart Jan Kullberg
MHMarlies E Hulscher
Marlies E Hulscher
JSJeroen A Schouten
Jeroen A Schouten
Background: Our aim in this study was to develop quality indicators (QIs) for outpatient parenteral antimicrobial therapy (OPAT) care that can be used as metrics for quality assessment and improvement. Methods: A RAND-modified Delphi procedure was used to develop a set of QIs. Recommendations on appropriate OPAT care in adults were retrieved from the literature using a systematic review and translated into potential QIs. These QIs were appraised and prioritized by a multidisciplinary panel of international OPAT experts in 2 questionnaire rounds combined with a meeting between rounds. Results: The procedure resulted in 33 OPAT-specific recommendations. The following QIs that describe recommended OPAT care were prioritized by the expert panel: the presence of a structured OPAT program, a formal OPAT care team, a policy on patient selection criteria, and a treatment and monitoring plan; assessment for OPAT should be performed by the OPAT team; patients and family should be informed about OPAT; there should be a mechanism in place for urgent discussion and review of emergent clinical problems, and a system in place for rapid communication; laboratory results should be delivered to physicians within 24 hours; and the OPAT team should document clinical response to antimicrobial management, document adverse events, and monitor QIs for OPAT care and make these data available. Conclusions: We systematically developed a set of 33 QIs for optimal OPAT care, of which 12 were prioritized by the expert panel. These QIs can be used to assess and improve the quality of care provided by OPAT teams.